24/7 Market News Snapshot 16 July, 2025 – CVRx, Inc. Common Stock (NASDAQ:CVRX)

July 16, 2025

DENVER, Colo., 16 July, 2025 (www.247marketnews.com) – (NASDAQ:CVRX) are discussed in this article.
CVRx, Inc. has recently gained significant traction in the market, with its stock price soaring to $8.534, reflecting a remarkable increase of over 20% from the previous close of $7.100. This upward momentum follows strong engagement from investors, evidenced by a current trading volume of 510.95K shares. The surge in stock price comes at a pivotal time as CVRx is making notable advancements in the reimbursement landscape for its flagship product, Barostim, which has been instrumental in the treatment of heart failure.

The Centers for Medicare and Medicaid Services (CMS) has announced its proposal to maintain the Barostim implant procedure under the New Technology Ambulatory Payment Classification (APC) 1580, with an estimated payment rate of approximately $45,000 for outpatient procedures. This decision underscores the clinical significance of Barostim in managing heart failure. Furthermore, CMS has planned two additional key updates: a reassignment of Barostim to a higher-paying MS-DRG for inpatient procedures effective October 1, 2024, and a transition of the device from Category III to Category I CPT codes for physician payments starting January 1, 2026.

CVRx’s President and CEO, Kevin Hykes, expressed confidence in these developments, noting that they will significantly enhance patient access to Barostim for individuals suffering from heart failure with reduced ejection fraction. The favorable reimbursement proposals position Barostim as a critical component in heart failure management, potentially expanding its market adoption and supporting the company’s long-term growth strategies.

As the first FDA-approved technology utilizing neuromodulation for heart failure treatment, Barostim has received recognition for its innovative approach and is in compliance with the EU Medical Device Regulation. CVRx continues to commit to advancements in healthcare through its pioneering cardiovascular solutions, with an eye on improving patient outcomes in this vital area.

Related news for (CVRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.